TY - JOUR
T1 - BCR/ABL stimulates WRN to promote survival and genomic instability
AU - Slupianek, Artur
AU - Poplawski, Tomasz
AU - Jozwiakowski, Stanislaw K.
AU - Cramer, Kimberly
AU - Pytel, Dariusz
AU - Stoczynska, Ewelina
AU - Nowicki, Michal O.
AU - Blasiak, Janusz
AU - Skorski, Tomasz
PY - 2011/2/1
Y1 - 2011/2/1
N2 - BCR/ABL-transformed chronic myeloid leukemia (CML) cells accumulate numerous DNA double-strand breaks (DSB) induced by reactive oxygen species (ROS) and genotoxic agents. To repair these lesions BCR/ABL stimulate unfaithful DSB repair pathways, homologous recombination repair (HRR), nonhomologous end-joining (NHEJ), and single-strand annealing (SSA). Here, we show that BCR/ABL enhances the expression and increase nuclear localization of WRN (mutated in Werner syndrome), which is required for processing DSB ends during the repair. Other fusion tyrosine kinases (FTK), such as TEL/ABL, TEL/JAK2, TEL/PDGFβR, and NPM/ ALK also elevate WRN. BCR/ABL induces WRN mRNA and protein expression in part by c-MYC-mediated activation of transcription and Bcl-xL-dependent inhibition of caspase-dependent cleavage, respectively. WRN is in complex with BCR/ABL resulting in WRN tyrosine phosphorylation and stimulation of its helicase and exonuclease activities. Activated WRN protects BCR/ABL-positive cells from the lethal effect of oxidative and genotoxic stresses, which causes DSBs. In addition, WRN promotes unfaithful recombination-dependent repair mechanisms HRR and SSA, and enhances the loss of DNA bases during NHEJ in leukemia cells. In summary, we postulate that BCR/ABL-mediated stimulation of WRN modulates the efficiency and fidelity of major DSB repair mechanisms to protect leukemia cells from apoptosis and to facilitate genomic instability.
AB - BCR/ABL-transformed chronic myeloid leukemia (CML) cells accumulate numerous DNA double-strand breaks (DSB) induced by reactive oxygen species (ROS) and genotoxic agents. To repair these lesions BCR/ABL stimulate unfaithful DSB repair pathways, homologous recombination repair (HRR), nonhomologous end-joining (NHEJ), and single-strand annealing (SSA). Here, we show that BCR/ABL enhances the expression and increase nuclear localization of WRN (mutated in Werner syndrome), which is required for processing DSB ends during the repair. Other fusion tyrosine kinases (FTK), such as TEL/ABL, TEL/JAK2, TEL/PDGFβR, and NPM/ ALK also elevate WRN. BCR/ABL induces WRN mRNA and protein expression in part by c-MYC-mediated activation of transcription and Bcl-xL-dependent inhibition of caspase-dependent cleavage, respectively. WRN is in complex with BCR/ABL resulting in WRN tyrosine phosphorylation and stimulation of its helicase and exonuclease activities. Activated WRN protects BCR/ABL-positive cells from the lethal effect of oxidative and genotoxic stresses, which causes DSBs. In addition, WRN promotes unfaithful recombination-dependent repair mechanisms HRR and SSA, and enhances the loss of DNA bases during NHEJ in leukemia cells. In summary, we postulate that BCR/ABL-mediated stimulation of WRN modulates the efficiency and fidelity of major DSB repair mechanisms to protect leukemia cells from apoptosis and to facilitate genomic instability.
KW - Animals
KW - Cell Line, Tumor
KW - Chromosome Aberrations
KW - DNA Breaks, Double-Stranded
KW - DNA Repair
KW - DNA, Neoplasm/genetics
KW - Disease Progression
KW - Exodeoxyribonucleases/genetics
KW - Fusion Proteins, bcr-abl/genetics
KW - Genomic Instability
KW - Humans
KW - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
KW - Mice
KW - Oxidative Stress/genetics
KW - Phosphorylation
KW - Protein-Tyrosine Kinases/genetics
KW - RecQ Helicases/genetics
KW - Recombinant Fusion Proteins/genetics
KW - Werner Syndrome Helicase
UR - http://www.scopus.com/inward/record.url?scp=79551530347&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000286830300024&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1158/0008-5472.CAN-10-1066
DO - 10.1158/0008-5472.CAN-10-1066
M3 - Article
C2 - 21123451
SN - 0008-5472
VL - 71
SP - 842
EP - 851
JO - Cancer Research
JF - Cancer Research
IS - 3
ER -